LI-RADS v2018:利用钆塞酸增强MRI的辅助征象修正最终LI-RADS分类
回顾性分析100例肝细胞癌高危患者钆塞酸增强腹部MRI,比较仅用主要征象、用主要加辅助征象、以及用主要加辅助征象但排除钆塞酸特异性辅助征象时最终LI-RADS分类的变化。使用全部辅助征象时56.4%的肝脏观察最终分类改变,多数为LR-3的升高或降低;排除钆塞酸特异性辅助征象时30.9%改变,多数由LR-3升至LR-4。作者认为正确应用辅助征象有助于更一致的分类评估。
要点
- 使用全部辅助征象(含钆塞酸特异性)时56.4%的肝脏观察最终LI-RADS分类发生改变。
- 排除钆塞酸特异性辅助征象时30.9%的观察分类改变,多数由LR-3升至LR-4。
- 分类改变多数涉及LR-3,提示辅助征象对LR-3病例的降级或升级影响最大。
核心结论
- 使用LI-RADS v2018辅助征象可显著改变最终LI-RADS分类,尤其是使用钆塞酸特异性辅助征象时。
- 理解辅助征象的正确应用有助于使用者之间实现更一致的分类评估。
研究设计与样本
- 回顾性分析2017年1月1日至2018年3月23日间100例18岁及以上肝细胞癌高危患者的钆塞酸增强腹部MRI。
- 每例检查由一名接受过腹部 fellowship 培训的放射科医生审阅。
- 先仅根据主要征象对肝脏观察赋予LI-RADS分类,再审阅辅助征象并分别在有和无钆塞酸特异性辅助征象的情况下重新赋予分类。
诊断标准与关键数值
- 使用全部MRI辅助征象(含钆塞酸特异性)时,56.4%的肝脏观察最终LI-RADS分类发生改变,多数为从LR-3升高或降低。
- 不使用钆塞酸特异性辅助征象时,30.9%的观察最终LI-RADS分类发生改变,多数为从LR-3升至LR-4。
临床应用与阅片要点
- 在LI-RADS v2018分类中应用辅助征象时,需注意钆塞酸特异性辅助征象可明显改变最终分类,尤其影响LR-3观察的升降级。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To quantify how often the LI-RADS v2018 category changed when utilizing major features only, when utilizing major and ancillary features, and when utilizing major and ancillary features excluding gadoxetate-specific ancillary features.
METHODS: Retrospective analysis of 100 patients age 18 and older at high risk for hepatocellular carcinoma who had an MRI abdomen performed with intravenous contrast gadoxetate between 1/1/2017 and 3/23/2018. Each examination was reviewed by a body fellowship-trained radiologist. LI-RADS category was assigned to the liver observation after review of major features only. Ancillary features were then reviewed and LI-RADS category assigned both including and excluding ancillary features specific to gadoxetate.
RESULTS: Utilizing all MRI ancillary features, including those specific to gadoxetate, changed the final LI-RADS category in 56.4% of liver observations, the majority an increase or decrease from LR-3. When not including the ancillary features specific to gadoxetate, the final LI-RADS category changed in 30.9% of observations, the majority increasing from LR-3 to LR-4.
CONCLUSION: Utilizing LI-RADS v2018 ancillary features can significantly alter the final LI-RADS category, especially when using gadoxetate-specific ancillary features. Understanding the correct application of ancillary features for the final LI-RADS category helps implement a more consistent category assessment amongst users.
引用
- Boatright C, Peterson J, Williams VL, et al. LI-RADS v2018: utilizing ancillary features on gadoxetate-enhanced MRI to modify final LI-RADS category. Abdom Radiol (NY). 2020. PMID: 32189023. doi:10.1007/s00261-020-02479-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。